Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 3 studies | 60% ± 18% |
Insufficient scRNA-seq data for expression of SLCO1B1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 4950.43 | 226 / 226 | 94% | 127.93 | 382 / 406 |
esophagus | 23% | 0.94 | 327 / 1445 | 21% | 0.53 | 39 / 183 |
uterus | 27% | 1.37 | 46 / 170 | 5% | 0.14 | 24 / 459 |
intestine | 25% | 1.01 | 245 / 966 | 6% | 0.35 | 34 / 527 |
bladder | 24% | 1.14 | 5 / 21 | 7% | 0.16 | 35 / 504 |
pancreas | 20% | 0.92 | 66 / 328 | 10% | 0.28 | 18 / 178 |
thymus | 28% | 1.11 | 180 / 653 | 1% | 0.02 | 8 / 605 |
prostate | 27% | 1.50 | 66 / 245 | 2% | 0.04 | 9 / 502 |
lung | 16% | 0.60 | 94 / 578 | 10% | 0.37 | 118 / 1155 |
stomach | 19% | 0.91 | 70 / 359 | 5% | 0.09 | 14 / 286 |
ovary | 20% | 0.62 | 36 / 180 | 2% | 0.07 | 10 / 430 |
breast | 16% | 1.24 | 73 / 459 | 1% | 0.04 | 16 / 1118 |
adrenal gland | 16% | 0.52 | 40 / 258 | 1% | 0.01 | 2 / 230 |
peripheral blood | 16% | 1.24 | 145 / 929 | 0% | 0 | 0 / 0 |
brain | 15% | 0.47 | 401 / 2642 | 0% | 0.15 | 2 / 705 |
spleen | 15% | 5.53 | 35 / 241 | 0% | 0 | 0 / 0 |
skin | 9% | 0.67 | 166 / 1809 | 4% | 0.13 | 21 / 472 |
blood vessel | 12% | 0.42 | 157 / 1335 | 0% | 0 | 0 / 0 |
kidney | 10% | 0.46 | 9 / 89 | 1% | 0.05 | 8 / 901 |
heart | 11% | 0.43 | 92 / 861 | 0% | 0 | 0 / 0 |
adipose | 9% | 1.16 | 112 / 1204 | 0% | 0 | 0 / 0 |
muscle | 7% | 0.21 | 60 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0015721 | Biological process | bile acid and bile salt transport |
GO_0006811 | Biological process | monoatomic ion transport |
GO_0043252 | Biological process | sodium-independent organic anion transport |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0015732 | Biological process | prostaglandin transport |
GO_0070327 | Biological process | thyroid hormone transport |
GO_0042167 | Biological process | heme catabolic process |
GO_0015711 | Biological process | organic anion transport |
GO_0055085 | Biological process | transmembrane transport |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0015132 | Molecular function | prostaglandin transmembrane transporter activity |
GO_0015125 | Molecular function | bile acid transmembrane transporter activity |
GO_0015349 | Molecular function | thyroid hormone transmembrane transporter activity |
GO_0008514 | Molecular function | organic anion transmembrane transporter activity |
GO_0015347 | Molecular function | sodium-independent organic anion transmembrane transporter activity |
Gene name | SLCO1B1 |
Protein name | Organic anion transporting polypeptide Solute carrier organic anion transporter family member 1B1 (SLCO1B1) (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Organic anion transporter SLC21A6) (Sodium-independent organic anion-transporting polypeptide 2) (OATP-2) (Solute carrier family 21 member 6) Solute carrier organic anion transporter family member |
Synonyms | OATP1B1 LST1 OATP2 SLC21A6 OATPC |
Description | FUNCTION: Mediates the Na(+)-independent uptake of organic anions . Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) . Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop . Involved in the clearance of endogenous and exogenous substrates from the liver . Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition . May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs . May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate . May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver . Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment . Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions . . |
Accessions | Q05CV5 Q0VGM0 Q7Z4M3 Q9Y6L6 K4P1Y1 Q6NSF9 ENST00000256958.3 K4P403 K4PF41 |